This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
JAK/STAT in leukemia: a clinical update
Molecular Cancer Open Access 26 January 2024
-
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences
Journal of Clinical Immunology Open Access 04 May 2023
-
In vivo impact of JAK3 A573V mutation revealed using zebrafish
Cellular and Molecular Life Sciences Open Access 27 May 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dungarwalla M, Matutes E, Dearden CE . Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol 2008; 80: 469–476.
Soulier J, Pierron G, Vecchione D, Garand R, Brizard F, Sigaux F et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2001; 31: 248–254.
Vainchenker W, Constantinescu SN . JAK/STAT signaling in hematological malignancies. Oncogene 2013; 32: 2601–2613.
Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000; 95: 3891–3899.
Gritti C, Dastot H, Soulier J, Janin A, Daniel MT, Madani A et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 1998; 92: 368–373.
Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL et al. Array-based genomic resequencing of human leukemia. Oncogene 2010; 29: 3723–3731.
Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dave UP . FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011; 118: 3911–3921.
Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205: 751–758.
Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K et al. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol 2010; 92: 320–325.
Bouchekioua A, Scourzic L, de Wever O, Zhang Y, Cervera P, Aline-Fardinet A et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2013; e-pub ahead of print 14 June 2013; doi:10.1038/leu.2013.157.
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157–163.
Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905–1913.
Couronné L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E et al. STAT3 mutations identified in human hematological neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013; e-pub ahead of print 19 July 2013; doi:10.3324/haematol.2013.085068.
Acknowledgements
We are indebted to the French hematologists who provided patient samples: B Cazin (Lille); R Garand (Nantes); MJ Grange, V Leblond, F Nguyen Khac, H Merle-Beral, F Valensi, B Varet, I Radford-Weiss, O Hermine, R Delarue, V Levy, JC Brouet, P Rousselot (Paris); G Damaj (Creteil); X Troussard (Caen); S Daliphard, P Cornillet (Reims); D Lusina (Aulnay); K Ghomari (Beauvais); C Bertout (Brest); O Tournilhac (Clermond-Ferrand); M Maynadie (Dijon); V Izydirczyk (Le Havre); E Callet-Bauchu, B Coffier (Lyon); F Lellouche (Quimper). This work was supported by grants from the Institut National du Cancer (INCa), the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Institut Curie, Section de Recherche. This work is a part of the ‘Cancéropole Ile-de-France–Mouse models of human cancer’ program coordinated by M Giovannini. VJ is a recipient of grants from the Association pour la Recherche sur le Cancer (ARC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Bellanger, D., Jacquemin, V., Chopin, M. et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 28, 417–419 (2014). https://doi.org/10.1038/leu.2013.271
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.271
This article is cited by
-
JAK/STAT in leukemia: a clinical update
Molecular Cancer (2024)
-
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences
Journal of Clinical Immunology (2023)
-
In vivo impact of JAK3 A573V mutation revealed using zebrafish
Cellular and Molecular Life Sciences (2022)
-
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
Leukemia (2021)
-
Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders
Current Hematologic Malignancy Reports (2019)